# Arcutis Biotherapeutics Gains Following Bullish Research Initiation From Cantor Fitzgerald

- URL: https://stocks.freetheai.org/news/arcutis-biotherapeutics-gains-following-bullish-research-initiation-from-cantor-b646a6
- Published: 2026-10-15T18:06:02Z
- Category: analyst_ratings; sentiment: bullish; impact: medium
- Symbols: [NASDAQ:ARQT](https://stocks.freetheai.org/symbols/NASDAQ-ARQT), [NASDAQ:INCY](https://stocks.freetheai.org/symbols/NASDAQ-INCY)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

Shares of Arcutis Biotherapeutics, Inc. (ARQT) climbed sharply Thursday after financial firm Cantor Fitzgerald began analyzing the biopharmaceutical company with an Overweight rating and set a target price of $48. The upbeat forecast is driven by accelerating adoption of Zoryve, a daily non-hormonal treatment offered in both cream and foam options that health regulators in North America have authorized for multiple skin conditions, including plaque psoriasis, eczema, and seborrheic dermatitis.

The analyst's enthusiasm rests on robust sales momentum and favorable market conditions. Arcutis generated $129.9 million in net Zoryve revenue during the second quarter of 2026, representing a 59% rise compared to the same period a year earlier and a 23% gain over the previous quarter. Cantor noted that Zoryve holds an edge over rival medication Opzelura from Incyte Corporation (INCY), which bears a severe safety warning on its label and restrictions against ongoing long-term usage. If Zoryve secures a 15% to 20% share among topical steroid alternatives, annual peak revenues could reach between $2.6 billion and $3.5 billion.

Looking ahead, several potential milestones could expand the drug's addressable market. Regulatory authorities are currently evaluating a lower-dose cream formula for babies between 3 and 24 months old, with an expected ruling date of Feb. 23, 2027. Clinical development targeting additional conditions like vitiligo and hidradenitis suppurativa could also unlock broader revenue streams over time.

## Key points

- Cantor Fitzgerald launched coverage of Arcutis Biotherapeutics (ARQT) with an Overweight rating and a $48 target.
- Zoryve generated $129.9 million in second-quarter 2026 net sales, surging 59% from the prior year.
- Analysts believe Zoryve could achieve peak sales up to $3.5 billion by capturing up to one-fifth of the topical steroid market.
- Safety warnings and prescription limits on Incyte Corporation (INCY) competitor Opzelura provide Zoryve a commercial edge.
- Regulators are considering Zoryve for infant eczema, with a decision deadline scheduled for Feb. 23, 2027.

## Questions and answers

### Why did shares of Arcutis Biotherapeutics rise on Thursday?

Arcutis Biotherapeutics stock climbed after Cantor Fitzgerald initiated research coverage with an Overweight rating and a $48 price target, pointing to strong revenue expansion for the skin treatment Zoryve.

### How much revenue did Zoryve bring in during Q2 2026?

Zoryve produced $129.9 million in net product sales during the second quarter of 2026, which marked a 59% increase year over year and a 23% gain sequentially.

### What key regulatory milestone is Arcutis facing next?

Health regulators are reviewing a pediatric Zoryve cream formulation for infants aged 3 to 24 months, with an official target decision date set for Feb. 23, 2027.